drugset / Trial / NCT04742075
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
Phase 2
Active not recruiting
188 enrolled
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Arbeitsgemeinschaft Gynaekologische Onkologie Austria · collabBelgian Gynaecological Oncology Group · collabDutch Gynaecological Oncology Group · collabEuropean Network of Gynaecological Oncological Trial Groups (ENGOT) · collabHellenic Cooperative Oncology Group · collabNorth Eastern German Society of Gynaecological Oncology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This prospective, multicenter, open-label, randomized phase II maintenance study is evaluating the efficacy of UV1-olaparib-durvalumab combination as maintenance therapy after platinum combination therapy for BRCAwt patients with relapsed ovarian cancer.
Timeline
- Start
- 2021-12-15
- Primary completion
- 2026-05-01
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | UV1 | Peptide | 300 ug | — |